MedPath

Evaluation of Effect of Stopping Mass Azithromycin Treatment after five years

Not Applicable
Recruiting
Conditions
Eye Diseases
Trachoma
Registration Number
PACTR201211000437277
Lead Sponsor
The Carter Center
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
27
Inclusion Criteria

All districts in West Amhara that have completed five or more annual rounds of MDA with azithromycin and have been surveyed for impact will be eligible for inclusion into the study.

Exclusion Criteria

Districts where SAFE has been implemented for less than 5 years or where impact evaluations have showed prevalence of TF in children 1-9 years to be below 10% will not be included into the study. In the excluded districts, the SAFE strategy will be continued as per the WHO standards and national guidelines.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.